



Fig. 1

Plasma & blood concentration levels (nmol/L)




3/11


Plasma & blood concentration levels (nmol/L)




Plasma & blood concentration levels (nmol/L)



Plasma & blood concentration levels (nmol/L)




Plasma & blood concentration levels (nmol/L)




7/11


# Plasma & blood concentration levels (nmol/L)



Plasma & blood concentration levels (nmol/L)




Plasma & blood concentration levels (nmol/L)



10/11

# Plasma & blood concentration levels (nmol/L)



**A**\$2**0**3 Clinicopathologic features and outcome of 12 consecutive patients with relapsed acute promyelocytic leukemia treated with oral

Time from

11 m   15.6   2.1   87   59 d   1da   10 m   14.0   2.5   2.5   76 d   ATRA   10 m   13.4   2.1   20   32 d   ATRA   10 m   13.4   2.1   20   32 d   ATRA   10 m   14.0   2.5   2.5   76 d   ATRA   10 m   10 m   13.4   2.1   20   32 d   ATRA   10 m   10 m   14.5   2.4   177   33 d   17 m   12.2   0.8   84   51 d   17 m   12.2   0.8   84   51 d   17 m   12.2   0.8   84   51 d   16 m   17 m   12.2   0.8   14   28 d   16 m   17 m   12.2   0.8   14   28 d   16 m   17 m   12.3   14   28 d   17 m   12 m   1	CRHD, double valve rep		·(3 m) 6 m+	Ida	2	Ida	28 d	y	6.5	8.5	12.3	ALIXA TAILE		
R1   ATRA + Dauno	to high cumulative doses of						-		•	:	3			
R1   ATRA + Dauno   11 m   15.6   2.1   87   59 d   1da   CR   1da   13 m   14.0   2.5   2.5   76 d   ATRA   NR   -   (18 m)   19 m +   (18 m)   18 m +	Ida consolidation omitted due		(E E)			• Ida	44 d 22 d	97	0.6		240 m	ATRA + Dauno		1 ° M / 45
R1 ATRA + Dauno	•	14 m +	-(12 m)	•	·			:	5	•	3 !	i.v. $A_{2}O_{3} + Idn$ ATRA + Danno		0°F/18
***M/23 R1 ATRA+Dauno	to CRF		<b>.</b>			A 173	28 d	180	.9	.io	12 E	ATRA + Dauno /	ಜ	F/18
***M/23 R1 ATRA+Dauno	CRI due to DM on CAPD,		-(12 m)	•		·	28 d	14	2.8	. 7.2	3	Š		_
M/23 R1 ATRA + Dauno	•	1/ m +	(III 127) •	-	;					:	•	1.V. A32C3 + Ida		
M/23 R1 ATRA+Dauno 11 m 15.6 2.1 87 59 d Ida CR Ida (18 m) 19 m+  K/13 R2 Dauno /i.v. As <sub>2</sub> O <sub>3</sub> + Ida 25 m 13.4 2.1 20 32 d ATRA CR As <sub>2</sub> O <sub>3</sub> + ATRA - (18 m) 19 m+  K/13 R2 ATRA+I.v. As <sub>2</sub> O <sub>3</sub> 10 m 8.6 1.2 15 30 d ATRA CR As <sub>2</sub> O <sub>3</sub> + ATRA - (18 m) 19 m+  M/32 R1 ATRA+Dauno 100 m 8.5 34.8 81 40 d Ida CR Ida - (18 m) 18 m+  K/32 R1 ATRA+Dauno 12 m 14.5 2.4 177 33 d CR Ida - (18 m) 18 m+  K/32 R1 ATRA+Dauno 12 m 12.2 0.8 84 51.4 CR Ida - (18 m) 18 m+	•	: m +	(12 =)	AirO. + ATTO A	-	ATRA	37 d			11.2	17 m	ATRA + Davino /		7° F/45
M/23 R1 ATRA+Dauno 11 m 15.6 2.1 87 59 d Ida CR Ida 13 m 14.0 2.5 25 76 d ATRA NR + (dead) 19 m 15.7 11 R2 ATRA+Iv. As <sub>2</sub> O <sub>3</sub> + Ida 25 m 13.4 2.1 20 32 d ATRA CR As <sub>2</sub> O <sub>3</sub> + ATRA - (18 m) 19 m + M/54 R1 ATRA+Dauno 100 m 8.5 34.8 81 40 d Ida CR Ida - (18 m) 19 m + M/32 R1 ATRA+Dauno 100 m 8.5 34.8 81 40 d Ida CR Ida - (18 m) 18 m + M/32 R1 ATRA+Dauno 100 m 8.5 34.8 81 40 d Ida CR Ida - (18 m) 18 m + (18 m)	•	18 m +	(18 m)	Loa		. •	2 6			12.2	2 3	ATTA + Dauno	~	6 F/32
M/23 R1 ATRA+Dauno 11 m 15.6 2.1 87 59 d Ida CR Ida 13 m 13.0 2.5 25 76 d ATRA NR + (dead) 13 m 15.1 R2 Dauno /i.v. As <sub>2</sub> O <sub>3</sub> + Ida 25 m 13.4 2.1 20 32 d ATRA CR As <sub>2</sub> O <sub>3</sub> + ATRA - (18 m) 19 m + M/54 R1 ATRA+Dauno 100 m 8.5 14.8 81 40 d ATRA CR As <sub>2</sub> O <sub>3</sub> + ATRA - (18 m) 19 m + M/54 R1 ATRA+Dauno 100 m 8.5 14.8 81 40 d ATRA CR As <sub>2</sub> O <sub>3</sub> + ATRA - (18 m) 19 m + M/54 R1 ATRA+Dauno 100 m 8.5 14.8 81 40 d ATRA CR As <sub>2</sub> O <sub>3</sub> + ATRA - (18 m) 19 m + M/54 R1 ATRA+Dauno 100 m 8.5 14.8 81 40 d ATRA CR As <sub>2</sub> O <sub>3</sub> + ATRA - (18 m) 19 m + M/54 R1 ATRA+Dauno 100 m 8.5 14.8 81 40 d ATRA CR As <sub>2</sub> O <sub>3</sub> + ATRA - (18 m) 19 m + M/54 R1 ATRA+Dauno 100 m 8.5 14.8 81 40 d ATRA CR As <sub>2</sub> O <sub>3</sub> + ATRA - (18 m) 19 m + M/54 R1 ATRA+Dauno 100 m 8.5 14.8 81 40 d ATRA CR As <sub>2</sub> O <sub>3</sub> + ATRA - (18 m) 19 m + M/54 R1 ATRA+Dauno 100 m 8.5 14.8 81 40 d ATRA CR As <sub>2</sub> O <sub>3</sub> + ATRA - (18 m) 19 m + M/54 R1 ATRA+Dauno 100 m 8.5 14.8 81 40 d ATRA CR As <sub>2</sub> O <sub>3</sub> + ATRA - (18 m) 19 m + M/54 R1 ATRA+Dauno 100 m 8.5 14.8 81 40 d ATRA CR As <sub>2</sub> O <sub>3</sub> + ATRA - (18 m) 19 m + M/54 R1 ATRA+Dauno 100 m 8.5 14.8 81 40 d ATRA CR As <sub>2</sub> O <sub>3</sub> + ATRA - (18 m) 19 m + M/54 R1 ATRA+Dauno 100 m 8.5 14.8 81 40 d ATRA CR As <sub>2</sub> O <sub>3</sub> + ATRA - (18 m) 19 m + M/54 R1 ATRA+Dauno 100 m 8.5 14.8 81 40 d ATRA CR As <sub>2</sub> O <sub>3</sub> + ATRA - (18 m) 19 m + M/54 R1 ATRA+Dauno 100 m 8.5 14.8 81 40 d ATRA CR As <sub>2</sub> O <sub>3</sub> + ATRA - (18 m) 19 m + M/54 R1 ATRA+Dauno 100 m 8.5 14.8 81 40 d ATRA CR As <sub>2</sub> O <sub>3</sub> + ATRA - (18 m) 19 m + M/54 R1 ATRA+Dauno 100 m 8.5 14.8 81 40 d ATRA CR As <sub>2</sub> O <sub>3</sub> + ATRA - (18 m) 19 m + M/54 R1 ATRA+Dauno 100 m 8.5 14.8 81 40 d ATRA CR As <sub>2</sub> O <sub>3</sub> + ATRA - (18 m) 19 m + M/54 R1 ATRA+Dauno 100 m 8.5 14.8 81 40 d ATRA CR As <sub>2</sub> O <sub>3</sub> + ATRA - (18 m) 19 m + M/54 R1 ATRA+Dauno 100 m 8.5 14.8 81 40 d ATRA+Dauno 100 m 8.5 14.8 81	mother: AML	18 m+	(18 m)	i da	٠	, C	۲ د د			14.5	22 m	ATRA + Dauno + MP	<b>R</b> 1	S* M/ 32
M/23 R1 ATRA+Dauno 11 m 15.6 2.1 87 59 d Ida CR Ida 13 m 14.0 2.5 25 76 d ATRA NR + (dead) 13 m 15.4 2.1 20 32 d ATRA CR Ango+ATRA - (18 m) 19 m+	•	19 m +	(18 m)	AS <sub>2</sub> O <sub>3</sub> + ATRA		5	> c			8	8	ATRA + Dauno	2	
M/23 R1 ATRA + Dauno 11 m 15.6 2.1 87 59 d Ida CR Ida 13 m 13.m 14.0 2.5 25 76 d ATRA NR + (dead)	•	19 m.+	(18 m)	ASO + AIKA		3	بر ا ا ا			8	;; ∃	ATRA + i.v. As,0,	ສ	
M/23 R1 ATRA+Dauno 11 m 15.6 2.1 87 59 d lda CR Ida 13 m 13 m 14.0 2.5 25 76 d ATRA ND				· ·	Ī	À ;	3 ;			13.4	;; ;;	Dauno /i.v. As <sub>2</sub> O <sub>3</sub> + Ida	23	
RI ATRA + Dauno 11 m 15.6 2.1 87 59 d 1da CP 14.		E B	:	1CIA	ş ş	A (TT) A	25.		_	14.0	E O	i.v. A22O3 + Ida	Z	
previous induction treatment last CR. Hb. WBC Plat dumition additional Rx result. Consolidation PCR1 DFS		<b>;</b>		Ţ	3	j.	P 65			15.6	=	ATRA + Dauno	R	1 · M/23
previous induction treatment last CR Hb WBC Plat dimition additional by	Remarks	SEC	Š	Consoligation	result	The second secon				١				
		}			2001	n additional De	duratio	5	₩D		last CR	previous induction treatment	SUIFIC	36 V V 28

<sup>\*:</sup> pharmacokinetic data of oral As<sub>2</sub>O<sub>3</sub> have previously been reported 1: PCR for PML/RARA, +: positive, -:negative, (time from initial diagnosis)

ni: months; d; days; DFS: disease free survival M: male; F: female, CR: complete remission; NR: non-remission; R1: first relapse; R2: second relapse CBC: complete blood count; Hb: hemoglobin (g/dL); WBC: white blood cell count (x 10°/L); Plat: platelet count (x 10°/L)

ATRA: all-trans retinoic acid; Dauno: daunorubicin; Ida: idarubicin; Ara-c: cytosine arabinoside CA: carcinoma; AML: acute myeloid leukemia; CRF: chronic renal failure; DM: diabetes mellitus CAPD: continuous ambulatory peritoneal dialysis; CRHD: chronic rheumatic heart disease; rep: replacement